Chembio Diagnostics, Inc., announced that it has entered into a worldwide strategic partnership with LumiraDx Limited to develop point-of-care (POC) diagnostic tests for the detection of the COVID-19 virus and IgM and IgG antibodies on both the LumiraDx and Chembio DPP platforms.
“We are pleased to expand our relationship with Chembio as our partner given the company’s expertise and speed in developing high-quality point-of-care assays. By joining forces and bringing together the best of these two companies, we believe we will become the chosen approach for the detection and monitoring of the COVID-19 virus, which has become a worldwide pandemic,” stated Ron Zwanziger, LumiraDx's Chairman and Chief Executive Officer.
Gail Page, Chembio's Interim Chief Executive Officer, added, "We are very excited to join with LumiraDx in this strategic partnership, which demonstrates our scientific expertise and the versatility of our DPP platform. Through our joint efforts, we expect the new products to provide comprehensive solutions to the new demands surrounding the worldwide testing needs for COVID‑19.”
